|Table of Contents|

Expression of CD13 and CD33 in bone marrow of patients with BCR-ABL+ acute lymphoblastic leukemia and their correlation with clinical features and prognosis

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 09
Page:
1720-1725
Research Field:
Publishing date:

Info

Title:
Expression of CD13 and CD33 in bone marrow of patients with BCR-ABL+ acute lymphoblastic leukemia and their correlation with clinical features and prognosis
Author(s):
HU Zhongli1; YANG Yanli1; ZHANG Pingping1; PAN Shaojun2
1.Department of Hematology，the First Affiliated Hospital of Bengbu Medical College，Anhui Bengbu 233003，China;2.School of Biomedical Engineering，Shanghai Jiao Tong University，Shanghai 200240,China.
Keywords:
acute lymphoblastic leukemia; BCR-ABL; CD13; CD33; overall survival rate
PACS:
R733
DOI:
10.3969/j.issn.1672-4992.2023.09.026
Abstract:
Objective:To investigate the expression of myeloid antigens CD13 and CD33 in bone marrow of patients with BCR-ABL+ acute lymphoblastic leukemia and their correlation with clinical features and prognosis.Methods:RQ-PCR was used to detect the expression level of BCR-ABL in bone marrow of 119 patients with newly diagnosed ALL，and the expression level of ALL antigen was detected by flow cytometry.The difference between CD13+ and CD13- and CD33+ and CD33- patients in CR1 and OS was analyzed.Results:In ALL patients with BCR-ABL+，CD13+ patients had a lower initial-induction remission rate than CD13- patients at initial diagnosis，and the difference was statistically significant(P＜0.05)，but there was no significant difference in the initial-induction remission rate between CD33+ patients and CD33- patients.The OS of CD13+ and CD33+ groups were significantly lower than that of CD13- and CD33- groups(P＜0.05).Conclusion:CD13+ and CD33+ in BCR-ABL+ ALL patients indicate poor prognosis.

References:

［1］DAVIS KL.Understanding the hematopoietic factory during acute lymphoblastic leukemia［J］.Pediatric Research，2022，91(5)：1023-1024.
［2］WANG HF，YANG C，SHI T，et al.Venetoclax-ponatinib for T315I/compound-mutated Ph+ acute lymphoblastic leukemia［J］.Blood Cancer Journal，2022，12(1)：18-20.
［3］CANDONI A，LAZZAROTTO D，RAMBALD A，et al.Effect of prophylactic or pre-emptive use of tyrosine kinase inhibitors post-Allo SCT in bcr-abl positive acute lymphoblastic leukemia：a subanalysis of GITMO ph-positive ALL study［J］.Bone Marrow Transplantation，2022，57(5):834-836.
［4］AULA I，BASSAM H.Prognostic value of myeloid antigens expression in childhood acute lymphoblastic leukemia［J］.Iraqi Journal of Hematology，2017，6(1):12-16.
［5］REZAEI MS，ESFANDIARI N，REFOUA S，et al.Characterization of immunophenotypic aberrancies in adult and childhood acute lymphoblastic leukemia：Lessons from regional variation［J］.Iranian Journal of Pathology，2020，15(1):1-7.
［6］ MOHAMED S，MOHAMED EL，RANDA N，et al.Reduction in the numbers of CD33+ myeloid population in Egyptian children with B-linage acute lymphoblastic leukemia and its recovery after induction of chemotherapy［J］.Clinical Cancer Investigation Journal，2015，4(5):627-632.
［7］沈悌，赵永强.血液病诊断及疗效标准［M］.4 版．北京：科学出版社，2018:160-170. SHEN T，ZHAO YQ.Diagnosis and curative effect criteria for blood diseases［M］.4th ed.Beijing：Science Press，2018：160-170.
［8］SHI T，XIE M，CHEN L，et al.Distinct outcomes，ABL1 mutation profile，and transcriptome features between P190 and P210 transcripts in adult Philadelphia-positive acute lymphoblastic leukemia in the TKI era［J］.Experimental Hematology & Oncology，2022，11(1):13-14.
［9］CIMINO G，PANE F，ELIA L，et al.The role of BCR/ABL isoforms in the presentation and outcome of patients with Philadelphia-positive acute lymphoblastic leukemia：a seven-year update of the GIMEMA 0496 trial［J］.Haematologica，2006，91(3):377-380.
［10］STIREWALT DL，GUTHRIE KA，BEPPU L，et al.Predictors of relapse and overall survival in Philadelphia chromosome-positive acute lymphoblastic leukemia after transplantation［J］.Biol Blood Marrow Transplant，2003，9(3)：206-212.
［11］KANTATARJIAN HM，TALPAZ M，DHINGRA K，et al.Significance of the P210 versus P190 molecular abnormalities in adults with Philadelphia chromosome-positive acute leukemia［J］.Blood，1991，78(9)：2411-2418.
［12］FAZIO F，CUNSOLO G.Blast morphology in the diagnostic work-up of Ph-like acute lymphoblastic leukemia［J］.Leukemia & Lymphoma，2022，63(6):1-3.
［13］KONG Y，XU LP，LIU YR，et al.Presence of CD34(+)CD38(-)CD58(-) leukemia-propagating cells at diagnosis identifies patients at high risk of relapse with Ph chromosome-positive ALL after allo-hematopoietic SCT［J］.Bone Marrow Transplantation，2015，50(3):348-353.
［14］JAWAD A，KHAN SA.Aberrant expression of myeloid antigens in patients of acute lymphoblastic leukaemia［J］.The Journal of the Pakistan Medical Association，2022，72(3):424-429.
［15］MODVIG S，WERMERSSON R.High CD34 surface expression in BCP-ALL predicts poor induction therapy response and is associated with altered expression of genes related to cell migration and adhesion［J］.Molecular Oncology，2022，16(10):2015-2030.
［16］NETANEL A,HOROWITZ JM.Advances in BCR/ABL positive ALL［J］.Advances in Cell and Gene Therapy，2019，2(3):466-468.
［17］LEONARD J，KOSAKA Y，MALLA P，et al.Concomitant use of a dual ABL/Src kinase inhibitor eliminates the in vitroefficacy of blinatumomab against Ph+ ALL［J］.Blood，2020(05):655-658.
［18］BRIAN IV BEN F，FREEDMAN TANYA S.The Src-family kinase Lyn in immunoreceptor signaling［J］.Endocrinology，2021，162(10)：152-155.
［19］HUNTER KD，PARKINSON EK，HARRISON PR.Profiling early head and neck cancer［J］.Nat Rev Cancer，2005，5(2):127-135.

Memo

Memo:
国家重点研发计划项目（编号：2017YFA0205300）；安徽高校自然科学研究项目（编号：KJ2019A0358）
Last Update: 2023-03-30